Roche to Use Endo-PAT in Clinical Trial

Itamar Medical Ltd. announced last week that it will include its Endo-PAT device with Swiss pharmaceutical company Roche Products Ltd. in a Phase II clinical trial of a drug for the treatment of peripheral arterial disease. Roche will pay $2.7 million for use of the device, which monitors the function of the interior layer of blood vessels.

According to studies by Itamar, the data collected by the Endo-PAT device makes it possible to assess damage in arterial walls. Roche’s use of the device in its own clinical trials essentially certifies Itamar’s own studies.

Itamar Medical president and CEO Dr. Dov Rubin said, “This collaboration strengthens our strategy of using the EndoPAT in a key role in the customized pharmaceutical and diagnostic industry.”

New Endothelial Dysfunction Study Unveiled at ACC 2010

Watch Dr. Matsuzawa lecture on “Digital Assessment of Endothelial Function and Ischemic Heart Disease in Women,” a study performed using EndoPAT technology by Itamar Medical. These are his remarks at ACC 2010:

Medvica, Endo-PAT Featured on KOLD-13 in Tucson

Endo-PAT was featured on a news segment in Tucson, Arizona following the first sale of the device in Arizona by Medvica. Here’s a link to the video:

New York Dentist Using Endo-PAT for Patients

New York City dentist Dr. Reid Winick has been using the Endo-PAT in his dental practice as part of a total wellness program for his patients. With the information gathered from the test, Dr. Winick and his colleagues put their patients on a personalized wellness program and thus a new lease on life.

Dr. Winick says he feels, “we are saving lives one tooth at time.” According to Winick’s web site, the dentist:

“Uses all the knowledge and skills of conventional dental medicine — along with disciplines of alternative, holistic dental therapies — we strive to provide our patients with biocompatible, esthetic, comfortable, functional, and enduring dental and prosthetic placements.”

For more information on endothelial dysfunction and the Endo-PAT, visit www.medvica.com.